Cambridge Healthtech Institute’s 2^nd Annual

Strategic Alliance Management Congress Europe

Advancing Pharmaceuticals through Collaborations & Partnerships

3-5 December 2018

As the biopharmaceutical industry continues to rely on alliances and collaboration with external organizations to access innovation and obtain market access, internal teams are often confronted with the increasing complexities of systematically and effectively managing partnerships throughout their lifecycle. The function and organizational capability of Alliance Management is now recognized as a critical means to ensure the successful execution of any strategic partnership, acting as a central driver of value, while alleviating aggravations, and meeting alliance goals.

Now in its second year, Strategic Alliance Management Europe will again unite senior alliance management, business development, project management, technology transfer, and licensing professionals to network, discuss case studies, and share the components that cultivate successful partnerships. Delegates will gain strategic insights, proven tools, methods, and perspectives from a variety of leaders advancing the art of Alliance Management.

Final Agenda

Day 1 | Day 2 | Day 3 | Download Brochure

Monday 3 December 2018

11:00 Registration

KEYNOTE SESSION

13:55 Organizer's Welcome and Chairperson’s Opening Remarks

Kaitlin Kelleher, Conference Director, Cambridge Healthtech Institute
Dana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

14:00 Welcome Progress with Observations on Partnering

Hughes_J-Dana Dana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

As we gather for another year of discussions and the sharing of stories from our organizations, we wanted to start with some framing on the current state of the marketplace. This short presentation will set the stage for the conference and prepare everyone for a deeper interactive discussion at the end of the day in the form of the “Big Pharma-Biotech Back-and-Forth: Tell Me What’s Wrong, and How I Can Help!”.

14:15 Diverse Models for a Diverse Portfolio: External and Internal Governance for Strategic Alliances

Stilz_Uli Uli Stilz, PhD, Vice President, Alliances & Innovation Outreach, Novo Nordisk

Experiences and specific learnings from different industry-academia collaboration models Novo Nordisk has been using to foster biomedical innovation at the interface between academic and industrial research will be discussed. Each collaboration model has been designed to address distinct business needs. Alignment on strategic objectives and business needs, anchoring within business functions, and strong alliance management support have been instrumental to create value for the collaborating parties.

14:45 CO-PRESENTATION: Strategic Alliances and Brexit

Ambwani_Karan Karan Ambwani, Head of Strategic Projects, EU & International Market, Teva

Tyssier_Erick Erick Tyssier, Head, Government Affairs Europe, Teva

We will discuss managing the impact of Brexit on European-wide strategic alliances.

15:15 Pharma-Biotech Back-and-Forth: Tell Me What’s Wrong, and How I Can Help!

Hughes_J-Dana Dana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

Join a frank, open (and ideally fun) ice-breaking exercise meant to involve all conference participants on those real issues that time and again rise in partnerships between large and small companies. Often each side is unaware of how to improve alignment with their partner. This session provides attendees with a safe means to expose these frequent pain-points and hear the perspective of “the other side.” If successful we will have the opportunity to discuss potential practices to alleviate common issues and ideate on more difficult issues.

16:00 Welcome Reception

17:00 End of Day

Day 1 | Day 2 | Day 3 | Download Brochure

Tuesday 4 December 2018

7:30 Morning Coffee

8:25 Chairperson’s Remarks

Uli Stilz, PhD, Vice President, Alliances & Innovation Outreach, Novo Nordisk

8:30 Evolving Alliance Management Practices at Boehringer Ingelheim

Walke_Stefan Stefan Walke, PhD, Head, Contracts and Alliance Management (CAM), Europe, Boehringer Ingelheim

This talk will discuss how Boehringer Ingelheim is moving from a project alliance management model to a portfolio alliance management model. We will address how to assess internal teams, split resources, and determine how much alliance management is needed per project.

9:00 J&J Innovation and the Evolving Alliance Management Role

Benz_Patrick Patrick Benz, PhD, Senior Director Alliance Management, Janssen Business Development (JBD), Janssen

Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities. Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, developments, and commercial partnerships. Such long-term collaborations need an appropriate Alliance Management Structure to meet the high expectations.

9:30 Evolution of Alliance and Integration Management at UCB: Key Aspects and Lessons Learned

Rahim_George George Rahim, PhD, Senior Director, Alliance & Integration Management, UCB Biopharma SPRL

The recent creation of Corporate Strategy & Development ( CS&D) organization within UCB ensures a holistic approach to partnerships and acquisitions, improving external and internal collaboration and knowledge sharing. The position of Alliance & Integration Management within CS&D alongside Scouting, Business Development and M&A strengthens our connections and complement the end to end partnering process, allow for aligned partnership management, thus increasing our impact in maximizing the value on our Alliances for partners, patients and UCB. We share the evolution of our approach to Alliance and Integration management at UCB and our learnings during this period.

10:00 Coffee Break

10:45 Alliance Management Capability Development

Huwe_Christoph Christoph Huwe, PhD, CSAP, Strategic Alliance Manager Therapeutics, Global External Innovation & Alliances, Bayer AG Pharmaceuticals

New developments in the healthcare industry will likely increase the number and complexity of alliances. This will require higher alliance capability levels and a broader distribution of alliance skills throughout the organizations involved. Using Bayer Pharmaceuticals as an example the presentation will highlight this development and illustrate how to manage it using specialized alliance management core groups, an alliance community effort and alliance team qualification beyond the core groups.

11:15 Embedding Alliance Management Capabilities in a Fast-Growing Biotech Organization

Witte_Florian Florian Witte, Director, Alliance Management, Pieris Pharmaceuticals

Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. In the most recent past, Pieris has entered into three major strategic alliances in the field of respiratory and immuno-oncology to accelerate its transformation into a fully-integrated R&D and commercial organization. Full commitment and investment in alliance business as key value driver for the future consequentially comes with establishment of a dedicated alliance management function and with changing operational, structural and cultural aspects. The talk will describe the overall alliance management concept at Pieris, implementation of tools and techniques, change management as well as first steps in the long-term vision of becoming a “partner of choice.”

11:45 Alliance Management Community at UCB: 7 Key Success Factors

Vanderavero_Cecile Cécile Vanderavero, Alliance Management Community Engagement Lead, Alliance and Integration Management, UCB Biopharma

With hundreds of colleagues involved – in one way or another – in managing an external collaborations or partnerships, and only a few of them being full-time dedicated alliance managers (AM), the set up and management of an AM community has become critical in the development of the partnering capability across UCB. In this presentation, we will explain how the AM community was set up and how it is currently managed, what the main achievements are so far, and what the key success factors have been.

12:15 Networking Lunch

14:25 Chairperson’s Remarks

Christoph Huwe, PhD, CSAP, Strategic Alliance Manager Therapeutics, Global External Innovation & Alliances, Bayer AG Pharmaceuticals

14:30 The CRUK MedImmune Alliance Laboratory: An Innovative Alliance Model

Little_Julie Julie Little, Strategic Alliance Executive, Commercial Partnerships, Cancer Research UK

Our standalone laboratory brings together the charity Cancer Research UK and its expertise in cancer biology, the novel biology of academic scientists, and the world-class antibody engineering technology of MedImmune, the global biologics research and development arm of AstraZeneca. In a very collaborative environment, we work closely with academic scientists to access novel biology and targets to help translate their discoveries into cancer patient benefit. We will describe how the laboratory came about and how it operates, the value of such an alliance as well as lessons learnt now that the laboratory has been in existence for over 3 years.

15:00 CO-PRESENTATION: A Development Partnership – Palatin Technologies and AMAG Pharmaceuticals

Svahnqvist_Helene Hélène Svahnqvist, Senior Director, Alliance Management, AMAG Pharmaceuticals, Inc.

Rob Jordan, Vice President, Clinical Operations and Program Management/Alliance Management, Palatin

Managing through the details: How Alliance Management operationalized the license agreement and adapted throughout the partnership to ensure collaborative joint development.

15:45 CO-PRESENTATION: Building a Novel Cell Therapy Collaboration: The Regeneron-Bluebird Partnership

David Gold, PhD, Director, Strategic Alliances, Regeneron
Bharat Reddy, PhD, Associate Director, Business Development, bluebird bio

This summer Regeneron and bluebird bio entered into a new research collaboration focused on combining the research capabilities of two leaders in their respective fields. In launching the partnership, we have sought to align our research teams to build a cohesive team to rapidly move novel CAR-T and TCR therapeutics from the lab to the clinic and meet the needs of our patients.

16:30 Breakout Discussion Groups

Table 1: Alliance Management at the Forefront of Deal Making
Moderator: Colette Mitchem, MBA, Associate Director, Corporate and Business Development, Norgine Ltd.

At what point should Alliance Management get involved in the deal making process?
What contributions can an alliance manager make to the negotiation process?
How would a partner perceive Alliance Management at the table? What message would that deliver about your company’s approach to partnership?
What steps are required to gain alignment in your own organization about the role of Alliance Management in the deal making process?

Table 2: Alliance Launch
Moderator: Neil Jones, PhD, Senior Group Leader, Discovery Bioscience, Cancer Research UK Therapeutic Discovery Laboratories

How, if at all, does your organization employ a systematic approach to launch alliances?
What are the initial challenges, necessities and opportunities during an alliance launch?

Table 3: Introducing Alliance Management to a Growing Biotech Company
Moderators: Florian Witte, Director, Alliance Management, Pieris Pharmaceuticals
Henrik Sorensen, PhD, Head, Alliance & Portfolio Management, Immunocore, Ltd.

Which Alliance Management skills and tools do companies need to possess?
How can organizations develop a culture of open innovation?
What are the ways to create value and share it among stakeholders involved?
How do you get CEO and senior management engagement?

Table 4: The Bigger Picture: The Alliance Lifecycle – Managing Change and Termination
George Rahim, PhD, Senior Director, Alliance & Integration Management, UCB Biopharma SPRL

Patrick Benz, PhD, Senior Director Alliance Management, Janssen Business Development (JBD), Janssen

How can turnover positively or negatively impact an alliance?
What measures can be taken to ensure that turnover has little impact on the alliance relationships, goals, and achievements?
How can planning and communication successfully manage the end of the alliance lifecycle while preserving value and relationship?

Table 5: Collaborative Culture in Alliance Teams
Moderators: Christoph Huwe, PhD, CSAP, Strategic Alliance Manager Therapeutics, Global External Innovation & Alliances, Bayer AG Pharmaceuticals
Yuri Khakhanov, PhD, Director for Projects Development, Energy Efficiency Cluster, Skolkovo Innovation Center

How to prepare good collaboration within an alliance team
How to analyze the current level of collaboration
How to improve the collaborative behavior within a team

18:00 End of Day

Day 1 | Day 2 | Day 3 | Download Brochure

Wednesday 5 December 2018

7:30 Morning Coffee

8:25 Chairperson’s Remarks

Neil Jones, PhD, Senior Group Leader, Discovery Bioscience, Cancer Research UK Therapeutic Discovery Laboratories

8:30 Alliance Management: Maximizing Collaboration Efforts

Sorensen_Henrik Henrik Sorensen, PhD, Head, Alliance & Portfolio Management, Immunocore, Ltd.

This talk will address how Immunocore is maximizing collaboration efforts from deal-making through project management.

9:00 Collaborative Themed Drug Discovery Alliances at CRUK: The Art of Harmonizing “Herding Cats” and “Dancing with The Devil”

Jones_Neil Neil Jones, PhD, Senior Group Leader, Discovery Bioscience, Cancer Research UK Therapeutic Discovery Laboratories

CRUK Therapeutic Discovery Laboratories brings together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and our in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients. The talk will feature examples from our innovative drug discovery alliances and some of the tools and techniques we use to enable these collaborations to deliver their full potential.

9:30 A Portfolio Approach to Collaborations: Managing Alliance Networks in High-Tech

Khakhanov_Yuri Yuri Khakhanov, PhD, Director for Projects Development, Energy Efficiency Cluster, Skolkovo Innovation Center

Collaborative innovation has transformed the high-tech sector worldwide. Ecosystems emerged throughout the industry as many new alliance-based businesses were created. A portfolio approach to collaborations should be introduced to manage ecosystems where organizations require new alliance management tools and business models. The presentation discusses: portfolio approach to create innovative ecosystem – common success factors; synergy achieved in clusters of high-tech companies; portfolio optimization to provide maximum value to all partners.

10:00 Coffee Break

10:45 A Divestment Playbook: Tools and Lessons Learned from a Transition Lead

Cavalli_Elena Elena Cavalli, CSAP, Director - Alliance Management, Business Development, Astellas Pharma Europe

With the rapidly evolving external pressures in the pharmaceutical world, businesses need to have the capability to swiftly and efficiently divest the non-core assets to help divert resources into the priority products within the portfolio. This presentation will take a practical look at the value that the Alliance Management Professional can bring to the post-deal divestment management.

11:15 The Out-Licensing Alliance Lifecycle: From the Cradle to the Grave

Mitchem_Colette Colette Mitchem, Associate Director, Corporate and Business Development, Norgine Ltd.